BPH Laser Treatment Options
Cell proliferation was assessed by BrdU incorporation. The online version of this article doi As control, 5 samples of BPH tissues removed by transurethral resection were used. Patients, giving their informed written consent, that covered the use of their tissues for research purposes, were included in the prostate cancer database of the Pathology Unit, ASUR 9. Normal goat and rabbit serum were used as negative control. The percentage of positive cells determined over 10, events was analyzed on BPH ospedale a Mosca FACScan cytofluorimeter BD Bioscience and fluorescent intensity was expressed in arbitrary units on a logarithmic scale.
Finally, samples were washed with 0. Fluorochrome was excited with the line of an argon-kripton laser. Briefly fixed paraffin-embedded tissue slices were deparaffinized, rehydrated and washed with 0. Subsequently, samples were washed with 0. Merge images were obtained by using the DP controller software Olympus.
Then the capsule cups were loaded into the sensor chambers and BPH ospedale a Mosca chambers were perfused with running medium bicarbonate-free DMEM with 0. ECAR rate data were expressed as percentages of response respect to the baseline value.
Cells were harvested at day 2 post-transfection for analysis. All samples were assayed in triplicate in the same plate and in three different experiments. After trypsinization and washing in PBS supplemented with 0. Samples were analyzed by a FACScan cytofluorimeter as above described. Cell growth was BPH ospedale a Mosca by MTT assay.
Four replicates were used for each treatment. The highest doses that did not affect cell viability were used. Briefly, 1. The statistical significance was determined by one-way Anova or by 2-way Anova with Bonferroni post-test. No differences were found comparing vehicle-treated with untreated PC3 cells control. Approximately In addition double immunofluorescence, performed in the androgens BPH ospedale a Mosca cell line LNCaP, showed that about Data shown are representative of one out of three separate experiments.
Each point represents the expression level in a single subject. The horizontal bars within the plots indicate the median percentage for each group.
Data shown are representative of one of three separate experiments. The percentage increase of cell proliferation was evaluated with respect to vehicle-treated cells. Therefore, we investigated whether these receptors functionally interact each other.
Chromatin immunoprecipitation analysis revealed that TRPV1 BPH ospedale a Mosca a novel androgen receptor target gene in castration-resistant C PCa cells [ 27 ]. Similarly, decreased TRPV6 levels were detected in androgen-insensitive tumours after androgen deprivation therapy [ 2 ]. Competing interests. GS conceived the study, participated in its design with all authors, coordinated and helped to draft the manuscript with the assistance of all authors.
All authors read and approved the final manuscript. Maria Beatrice Morelli, Email: moc. Consuelo Amantini, Email: ti. Massimo Nabissi, Email: ti. Sonia Liberati, Email: ti. Claudio Cardinali, Email: ti. Valerio Farfariello, Email: rf. Daniele Tomassoni, Email: ti. Wilma Quaglia, Email: BPH ospedale a Mosca. Alessandro Piergentili, Email: ti. Alessandro Bonifazi, Email: ti. Fabio Del Bello, Email: ti. Matteo Santoni, Email: ti. Gabriele Mammana, Email: ti.
Lucilla Servi, Email: ti. Alessandra Filosa, Email: moc. Angela Gismondi, Email: ti. Giorgio Santoni, Email: ti. National Center for Biotechnology InformationU. BPH ospedale a Mosca Cancer. Published online Dec 7. Author information Article notes Copyright and License information Disclaimer. Corresponding author. Received Apr 29; Accepted Nov This article is published under license to BioMed Central Ltd. This article has been cited by other articles in PMC.
Representative immunoblots are shown. Electronic supplementary material The online version of this article doi Confocal laser scanning microscopy analysis 2. Statistical analysis The statistical significance was determined by one-way Anova or by 2-way Anova with Bonferroni post-test. Open in a separate window. Figure 1. Figure 2. Figure 3. Figure 4. Figure 5. Figure 6. Figure 7. Electronic supplementary material Additional file 1: Table S1: Patient demographics.
Footnotes Competing interests The authors BPH ospedale a Mosca that they have no competing interests. References 1. Nat Rev Cancer. Flourakis M, Prevarskaya N. Biochim Biophys Acta. Biochem Biophys Res Commun. Eur J Pharmacol.
Increased expression of cannabinoid receptor-1 and transient receptor potential vanilloi-1 in human prostate carcinoma. J Cancer Res Clin Oncol. International union of pharmacology nomenclature of adrenoceptors. Pharmacol BPH ospedale a Mosca. Localization and expression of the alpha 1A-1alpha 1B and alpha 1D -adrenoceptors in hyperplastic and non-hyperplastic human prostate.
J Urol. Regulation of the cellular localization and signaling properties of the alpha 1B - and alpha 1D -adrenoceptors by agonists and inverse agonists. Mol Pharmacol.
Docherty JR. Cell Mol Life Sci. Differences in the cellular localization and agonist-mediated internalization properties of the alpha 1 -adrenoceptor subtypes. Ernst Schering Found Symp Proc. Change of BPH ospedale a Mosca levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor-subtype-selective antagonist naftopidil BPH ospedale a Mosca benign prostate hyperplasia patients.
Terrillon S, Bouvier M. Roles of G-protein-coupled receptor dimerization. EMBO J. Dominance of the alpha1B-adrenergic receptor and its subcellular localization in human and TRAMP prostate cancer cell lines. J Recept Signal Transduct Res.